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Abstract
This study investigated whether common polymorphisms of cytochrome P450 2J2 (CYP2J2), a major enzyme that controls 
the biosynthesis of vasoactive epoxyeicosatrienoic acids, are collectively involved in the molecular basis of essential 
hypertension (EH). A total of 2314 unrelated Russian subjects from the Kursk (discovery sample: 913 EH patients and 645 
controls) and Belgorod (replication sample: 345 EH patients and 411 controls) regions were recruited for this study. Eight 
single nucleotide polymorphisms (SNPs), including rs890293, rs11572182, rs10493270, rs1155002, rs2280275, rs7515289, 
rs11572325, and rs10889162, of CYP2J2 were genotyped using the MassARRAY 4 system and TaqMan-based assays. 
Significant associations were identified among the SNPs rs890293 (OR =  2.17, 95%CI 1.30-3.65), rs2280275 (OR =  1.59, 
95%CI 1.10-2.37) and rs11572325 (OR =  1.89, 95%CI 1.22-2.95) and the risk of EH in females from the Kursk population. 
Sixteen CYP2J2 genotype combinations only showed significant associations with EH risk only in females. A common 
haplotype, T-T-G-C-C-C-T-A, increased the risk of EH in females. The bioinformatic analysis enabled identification of the 
SNPs that possess regulatory potential and/or are located within the binding sites for multiple transcription factors that 
play roles in the pathways involved in hypertension pathogenesis. Moreover, the polymorphisms rs890293, rs2280275, and 
rs11572325 were found to be significantly associated with hypertension risk in the Belgorod population. In conclusion, the 
rs2280275 and rs11572325 SNPs of CYP2J2 may be considered novel genetic markers of hypertension, at least in Russian 
women. However, sex-specific associations between CYP2J2 gene polymorphisms and hypertension require further 
investigation to clarify the specific genetic and/or environmental factors that are responsible for the increased disease 
susceptibility of women compared to that of men.
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Introduction
Essential hypertension (EH) represents a multifactorial 
disorder with a high worldwide prevalence and related 
increased rates of morbidity, mortality, and disability from 
cardiovascular and cerebrovascular complications [1, 2]. 
The mechanisms of blood pressure regulation are complex 
and are determined by tight interactions between various 
genetic and environmental factors [3, 4]. Candidate gene 
and genome-wide association studies have identified 
numerous genetic variants that influence blood pressure 
and hypertension susceptibility across different populations; 
nevertheless, few genetic loci have been successfully vali­
dated in independent studies [5- 8].
Despite the progress in the omics sciences in the previous 
decade, the molecular mechanisms of hypertension remain 
to be defined, such as the role of genes involved in the 
biosynthesis of vasoactive eicosanoids synthesized from 
arachidonic acid (AA) in disease pathogenesis. An 
increasing body of studies has provided compelling evi­
dence that epoxyeicosatrienoic acids (EETs), vasoactive 
products of AA derived from the cytochrome P450 
epoxygenase pathway, possess antihypertensive, anti­
inflammatory and cardioprotective properties [9- 11]. 
EETs regulate the vascular tone and fluid-electrolyte 
transport in cardiovascular and renal tissues, as well as 
protect cells against the oxidative stress induced by hypoxia 
and reoxygenation [10, 12, 13]. These biological functions 
made the metabolism of EETs an attractive pathway for 
investigating hypertension pathogenesis.
Cytochrome P-450 2J2 (CYP2J2), a major enzyme of the 
epoxygenase pathway in the heart and vasculature, meta­
bolizes AA to all four regioisomeric cis-EETs, including 
5,6-, 8,9-, 11,12- and 14,15-EETs [10, 13- 15]. Taking 
into account the multifaceted cardiovascular and renal 
actions of EETs, single nucleotide polymorphisms (SNP) 
of the CYP2J2 gene have become the targets for genetic 
association studies of cardiovascular disorders in various 
populations [16- 27]. However, a limited number of studies 
has been conducted to date to investigate the contribution 
of CYP2J2 gene polymorphisms to hypertension suscept­
ibility [28- 33]. Many of these association studies have 
shown inconsistent and inconclusive results, which may be 
due to different genetic factors underlying hypertension 
in diverse populations and different patterns of linkage 
disequilibrium between the investigated loci and the causal 
variant. Moreover, a substantial number of studies have 
been performed in populations with a small sample size 
and a limited number of CYP2J2 polymorphisms. Thus, 
there is a clear need for a large and comprehensive research 
study with numerous SNPs investigated simultaneously so 
that a true estimate of the hypertension risk related to 
CYP2J2 gene polymorphisms can be obtained within a
defined population. The present study was designed to 
investigate whether common polymorphisms of the CYP2J2 
gene are comprehensively involved in the molecular basis 
of EH.
Methods
Study participants
The study protocol was approved by the Ethical Review 
Committee of Kursk State Medical University and Belgorod 
State University, and written informed consent was 
obtained from all participants prior to recruitment. The 
discovery sample, including 1558 unrelated individuals 
(913 patients with EH and 645 age- and sex-matched 
healthy controls), was recruited from the Cardiology Clinics 
of Kursk Regional Clinical Hospital and the Neurology 
Clinics of Kursk Emergency Medicine Hospital. These 
study patients were enrolled during two study periods: the 
first period was between 2003 and 2006 and the second 
period was between 2007 and 2012 [34- 37]. The control 
group included blood donors, healthy volunteers and 
hospital-based patients (all subjects were recruited from the 
surgical, traumatic, and infectious divisions of Kursk hos­
pitals) with normal blood pressure and without cardiovas­
cular or other chronic diseases. The control group was 
recruited over the same periods of time [34- 38]. To ensure 
an ethnically homogeneous population, only Russian resi­
dents living in Central Russia for at least two generations 
have been included in the study. The replication population 
included DNA samples obtained from 756 unrelated Rus­
sian individuals (345 hypertensive patients and 411 con­
trols) as a part of the biobank of Belgorod State University. 
Detailed information regarding this population is described 
elsewhere [36].
The diagnosis of EH in both population samples was 
established by qualified cardiologists according to the 
WHO criteria or if patients had a history of receiving 
an antihypertensive drug. EH in untreated patients was 
defined as a seated systolic and/or diastolic blood pres­
sure above 140 and/or 90 mm Hg, respectively, during 
at least two separate measurements. All hypertensives 
included in the study had no clinical signs, symptoms, 
or laboratory findings suggestive of secondary hyper­
tension. All study subjects completed a questionnaire 
concerning conventional demographic characteristics, 
which are summarized in Table 1.
Selection of SNPs and genetic analysis
Potentially functional SNPs were selected using a set of 
web-based SNP selection tools available at SNPinfo Web
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Table 1 Baseline and clinical 
characteristics of the study 
populations
Baseline and clinical characteristics Healthy controls EH patients P-values
Discovery sample (Kursk region): 645 normotensive controls and 913 EH patients
Age mean ± S.D 58.7 ±7.6 58.4±8.9 0.49
Gender, N  (%) (M -  male, F- female) M 365 (56.6) 
F 280 (43.4)
M 488 (53.5) 
F 425 (46.5)
0.24
Mean systolic blood pressure (mm Hg) 124.7 ± 8.6 162.3 ± 10.2 <0.001
Mean diastolic blood pressure (mm Hg) 76.8 ±9.5 102.9 ±10.7 <0.001
Body mass index (kg/m2) 27.4±8.3 28.2 ±10.5 0.11
Positive family history of hypertension, N  (%) 312 (49.8) 568 (62.8) 0.004
Replication sample (Belgorod region): 411 population controls and 345 EH patients
Age mean ± S.D. 57.1 ±9.8 58.2±9.7 0.12
Gender, N  (%) (M -  male, F- female) M 260 (63.3) 
F 154 (36.7)
M 203 (58.8) 
F 142 (41.2)
0.24
Mean systolic blood pressure (mm Hg) NA 168.4 ±9.5 -
Mean diastolic blood pressure (mm Hg) NA 105.6 ±9.3 -
Body mass index (kg/m2) 25.6±3.8 26.1 ±4.6 0.12
Positive family history of hypertension, N  (%) NA NA -
Bolded is statistically significant P-value 
NA not available
Server (https://snpinfo.niehs.nih.gov). The selection of 
SNPs was based on their predicted functional character­
istics, minor allele frequency (MAF>5% in Europeans) and 
haplotype tagging properties. Initially, ten common SNPs 
were selected for the study. Two selected SNPs (rs2271800 
and rs10889160) showed too low genotype call rates 
(<60%) and were therefore excluded from the study. 
Although the polymorphism —76G>T (rs890293) showed 
a call rate of 81.5%, the SNP was included in the study 
because this functional polymorphism in the promoter of 
the CYP2J2 gene represents the most interesting genetic 
variant that has been intensively investigated in cardiovas­
cular diseases in different populations of the world. 
In addition, this SNP was found to be associated with 
hypertension risk in our preliminary study conducted on a 
small population sample of the Kursk region [31]. 
The average call rate for the remaining seven SNPs 
was 99.4% (Supplementary Table 1). Thus, eight SNPs, 
including rs890293, rs11572182, rs10493270, rs1155002, 
rs2280275, rs7515289, rs11572325 and rs10889162, of the 
CYP2J2 gene were included for statistical data analysis.
Total DNA was isolated from 5 ml peripheral blood 
samples obtained from all study subjects using standard 
procedures of SDS-proteinase K digestion, phenol/chloro- 
form extraction, and ethanol precipitation. SNP genotyping 
was performed by a matrix-assisted laser desorption/ioni- 
zation time-of-flight mass spectrometry (MALDI-TOF MS) 
iPLEX platform (Agena Bioscience, Inc., San Diego, CA, 
USA) at the Core Facility “Medical Genomics” in the 
Research Institute of Medical Genetics (Tomsk, Russia). 
The primer sequences used for genotyping the CYP2J2
polymorphisms are shown in Supplementary Table 1. 
Multiplex polymerase chain reaction was performed on 
the CFX96 Touch™ Real-Time PCR Detection System 
(Bio-Rad Laboratories, Hercules, CA, USA). Genotypes 
of CYP2J2 in the discovery population (Kursk region) 
were analyzed via the MassARRAY 4 system (Agena 
Bioscience, Inc., San Diego, CA, USA). The replication 
cohort (Belgorod region) was used for genotyping the 
SNPs that showed significant associations with hyperten­
sion risk in the discovery population. Genotyping was 
performed using TaqMan-based real-time PCR assays 
(Applied Biosystems, USA) on the CFX96 Touch™ Real­
Time PCR Detection System (Bio-Rad Laboratories, USA). 
Blind replicates were included for quality control. As 
quality controls, ~5% of the samples were randomly 
selected for repeated genotyping, and the analysis showed 
100% reproducibility of the initial genotyping results.
The genotype and mRNA expression data for the 
CYP2J2 gene obtained from the Genotype-Tissue Expres­
sion (GTEx) project were used to evaluate genotype- 
phenotype correlations [39, 40]. The GTEx project was 
created to establish a sample and data resource for studies 
on the relationship between genetic variation and gene 
expression in multiple human tissues. The expression levels 
were evaluated using the Affymetrix Expression Array at 
the GTEx Laboratory Data Analysis and Coordinating 
Center (Broad Institute) in samples of tibial arteries 
obtained from 285 postmortem individuals. The transcrip­
tion levels were called via the RNA-SeQC tool, after fil­
tering for unique mapping, proper pairing, and exon 
overlap. Genotyping data were obtained using the Illumina
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OMNI 5M SNP Array (a description of the laboratory 
methods is available at the website https://www.gtexportal. 
org/home/documentationPage#staticTextLabMethods).
Statistical and bioinformatic data analyses
Statistical power was estimated using the Genetic Associa­
tion Study (GAS) Power Calculator online (http://csg.sph. 
umich.edu/abecasis/cats/gas_power_calculator/index.html) 
assuming an EH prevalence of 40% and the existing sample 
sizes of 913 hypertensive patients and 645 healthy controls 
in Kursk population. Analysis of the association between 
various SNPs and hypertension risk (multiplicative model) 
could detect the genotype relative risk (GRR) of 1.25-1.41 
assuming 80% power and a 5% type I error (a =  0.05). 
Allele frequencies were estimated by the gene counting 
method: the total number of copies of an allele is calculated 
across the studied group by taking twice the number of 
homozygotes for this allele plus the number of hetero­
zygotes. The frequency of the allele is subsequently calcu­
lated as a proportion of the allele counts divided by 
double the total sample size. The chi-square test was used 
to identify significant departures from Hardy-Weinberg 
equilibrium. Categorical variables, such as sex and 
family history of hypertension, were compared using the 
chi-square test. SNPStats software [41] was applied to 
evaluate the frequencies of alleles, genotypes and haplotypes 
of CYP2J2. The strength of the association of alleles, 
genotypes and haplotypes with EH risk in gender- 
stratified groups was measured by multiple logistic regres­
sion analysis to calculate odds ratios (OR) with 95% con­
fidence intervals (CI) and adjusted for age and body mass 
index (BMI). A P-value < 0.05 was considered statistically 
significant. To control for multiple testing, false discovery 
rate (FDR) based Q-values were calculated for each SNP 
association using the method proposed by Benjamini and 
Hochberg [42] and implemented in the FDR calculator 
available online at http://www.sdmproject.com/utilities/? 
show=FDR.
The effects of the investigated SNPs on the CYP2J2 
mRNA levels (data from the GTEx project) were eval­
uated by T-statistics. The functionality of the SNPs 
was also assessed in silico by the SNP Function Predic­
tion tool developed by Xu and Taylor [43] and available 
online (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc. 
html). This tool utilizes the information of the TRANS- 
FAC database (BIOBASE Corporation, Wolfenbuettel, 
Germany) on potential transcription factor recognition 
sites. Only transcription factor binding sites (TFBS) 
for which the core or matrix match score was impacted 
or that were eliminated or created by variant sequences 
are considered to be regulatory within a particular 
SNP. rSNPBase, a database of curated regulatory SNPs
(http://rsnp.psych.ac.cn), was also used to analyze and 
interpret genotype-phenotype relationships [44].
Results
Associations between CYP2J2 gene polymorphisms 
and EH
The allele and genotype frequencies of the CYP2J2 gene 
polymorphisms in the discovery population stratified by 
gender are shown in Table 2. The observed genotype fre­
quencies of all SNPs in the case and control groups were in 
Hardy-Weinberg equilibrium (P > 0.05). The allele and 
genotype frequencies for the investigated CYP2J2 poly­
morphisms were in accordance with those reported in other 
European populations (SNP database, https://www.ncbi. 
nlm.nih.gov/snp). As shown in Table 2, allele —76T of SNP 
rs890293 showed an association with an increased risk of 
EH in females: the odds ratio adjusted for age and BMI 
(adjOR) was 2.05 (95%CI 1.23-3.39, P  =  0.004, Q = 0.02). 
A significant difference in the distribution of genotype 
—76G/T was identified between the hypertensive and nor- 
motensive females (adjOR =  2.17, 95%CI 1.30-3.65, P  =  
0.008, Q =  0.04). Moreover, two other polymorphisms, 
rs2280275, and rs11572325, of CYP2J2 were significantly 
associated with the risk of EH in females. In particular, 
allele C and genotype T/C of SNP rs2280275 were asso­
ciated with an increased risk of EH: adjOR =  1.50, 95%CI 
1.11-2.05, P  =  0.01, Q =  0.03 and adjOR =  1.59, 95%CI 
1.10-2.37, P  =  0.01, Q =  0.04, respectively. The increased 
risk of hypertension in females was also associated with a 
carriage of allele T and genotype A/T for SNP rs11572325: 
adjOR =  1.74, 95%CI, P =  0.06, Q =  0.02 and adjOR =  
1.89, 95%CI 1.22-2.95, P  =  0.02, Q =  0.05, respectively. 
As shown in Table 2, these associations remained statisti­
cally significant after adjustment for multiple testing (Q < 
0.05). Notably, no associations of the CYP2J2 gene poly­
morphisms with the risk of EH were identified in males (P 
> 0.05). We subsequently performed an association analysis 
for the polymorphisms that showed significant associations 
with EH risk in the discovery population (SNPs rs890293, 
rs2280275, and rs11572325). Table 3 shows the frequencies 
of the genotypes and alleles for the three CYP2J2 SNPs in 
Belgorod individuals. As shown in Table 3, these poly­
morphisms were found to be significantly (P < 0.05, Q < 
0.05) associated with hypertension risk in the Belgorod 
population. To assess whether estrogens contribute to 
hypertension in females, we analyzed the associations of 
SNPs rs890293, rs2280275 and rs11572325 with EH risk 
separately in pre- and post-menopausal women (i.e., women 
younger or 45 years old, respectively) from the Kursk 
population (all hypertensive women from the Belgorod
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Table 2 Genotype and allele frequencies for SNPs of the CYP2J2 gene in hypertensive patients and healthy controls (discovery population)
P o ly m o r p h i s m G e n o ty p e ,  a l l e l e M a l e s ,  N  ( % ) a F e m a l e s ,  N  ( % ) a
H e a l t h y  c o n t r o l s E H  p a t i e n t s P - v a l u e ( ) ~ v a lu e ad jO R  ( 9 5 %  C I ) b H e a l t h y  c o n t r o l s E H  p a t i e n t s P - v a l u e ( ) ~ v a lu e ad jO R  ( 9 5 %  C I ) b
r s S 9 0 2 9 3 G / G 2 5 3  ( 8 8 .2 ) 3 3 0  ( 8 7 .3 ) 0 .4 8 o.ss 1 .0 0 2 2 3  ( 9 0 .7 ) 2 9 2  ( 8 1 .3 ) 0.008 0.04 1 .0 0
G /T 3 4  ( 1 1 .8 ) 4 6  ( 1 2 .2 ) 1 .0 2  ( 0 . 6 3 - 1 . 6 7 ) 2 2  ( 8 .9 ) 6 4  ( 1 7 .8 ) 2 .1 7  ( 1 . 3 0 - 3 . 6 5 )
T /T 0  ( 0 .0 ) 2  ( 0 .5 ) - 1 ( 0 .4 ) 3  ( 0 .8 ) 1 .6 2  ( 0 .2 7 - 1 1 .4 3 )
T 3 4  ( 5 .9 ) 5 0  ( 6 .6 ) 0 .6 7 0 .9 9 1 .1 1  ( 0 . 7 1 - 1 . 7 6 ) 2 4  ( 4 .9 ) 7 0  ( 9 .7 ) 0.004 0.02 2 .0 5  ( 1 . 2 3 - 3 . 3 9 )
r s l l 5 7 2 1 S 2 T /T 2 6 6  ( 7 2 .9 ) 3 5 3  ( 7 2 .3 ) 0 .8 3 0 .9 5 1 .0 0 1 9 3  ( 6 8 .9 ) 3 1 0  ( 7 2 .9 ) 0 .5 2 0 .5 9 1 .0 0
T /G 9 1  ( 2 4 .9 ) 1 2 7  ( 2 6 .0 ) 1 .0 7  ( 0 . 7 9 - 1 . 4 8 ) 7 9  ( 2 8 .2 ) 1 0 5  ( 2 4 .7 ) 0 .S 2  ( 0 . 5 8 - 1 . 1 9 )
G / G 8  ( 2 .2 ) 8  ( 1 .6 ) 0 .7 3  ( 0 . 2 9 - 1 . 9 2 ) S ( 2 .9 ) 1 0  ( 2 .4 ) 0 .8 3  ( 0 . 3 5 - 2 . 0 1 )
G 1 0 7  ( 1 4 .7 ) 1 4 3  ( 1 4 .7 ) 0 .9 5 0 .9 9 1 .0 1  ( 0 . 7 7 - 1 . 3 6 ) 9 5  ( 1 7 .0 ) 1 2 5  ( 1 4 .7 ) 0 .3 0 0 .4 0 0 .8 1  ( 0 . 6 0 - 1 . 2 8 )
r s  1 0 4 9 3  2 7 0 G / G 2 9 4  ( 8 0 .8 ) 3 9 7  ( 8 1 .4 ) 0 .9 7 0 .9 7 1 .0 0 2 1 9  ( 7 8 .2 ) 3 3 7  ( 7 9 .3 ) 0 .S 7 0 .S 7 1 .0 0
G / A 6 7  ( 1 8 .4 ) 8 7  ( 1 7 .8 ) 0 .9 5  ( 0 . 6 7 - 1 . 3 8 ) 5 9  ( 2 1 .1 ) 8 6  ( 2 0 .2 ) 0 .9 4  ( 0 . 6 3 - 1 . 4 0 )
A / A 3  ( 0 .8 ) 4  ( 0 .8 ) 0 .9 5  ( 0 . 2 3 - 3 . 9 2 ) 2  ( 0 .7 ) 2  ( 0 .5 ) 0 .6 4  ( 0 . 1 0 - 3 . 8 7 )
A 7 3  ( 1 0 .0 ) 9 5  ( 9 .7 ) 0 .9 2 0 .9 9 0 .9 4  ( 0 . 6 9 - 1 . 3 6 ) 6 3  ( 1 1 .3 ) 9 0  ( 1 0 .6 ) 0 .7 9 0 .7 9 0 .9 2  ( 0 . 6 2 - 1 . 3 8 )
r s l  1 5 5 0 0 2 C /C 1 4 9  ( 4 1 .0 ) 1 6 8  ( 3 9 .9 ) 0 .0 9 0 .7 1 1 .0 0 1 1 0  ( 3 9 .4 ) 1 7 7  ( 4 4 .5 ) 0 .2 7 0 .4 3 1 .0 0
C /T 1 8 1  ( 4 9 .9 ) 1 9 3  ( 4 5 .8 ) 0 .8 3  ( 0 . 6 5 - 1 . 1 1 ) 1 2 4  ( 4 4 .4 ) 1 7 2  ( 4 3 .2 ) 1 .3 0  ( 0 . 9 5 - 1 . 8 1 )
T /T 3 3  ( 9 .1 ) 6 0  ( 1 4 .3 ) 1 .6 2  ( 1 . 0 1 - 2 . 4 2 ) 4 5  ( 1 6 .1 ) 4 9  ( 1 2 .3 ) 0 .S 7  ( 0 . 5 6 - 1 . 3 9 )
T 2 4 7  ( 3 4 .0 ) 3 1 3  ( 3 7 .2 ) 0 .2 2 0 .9 9 1 .1 2  ( 0 . 9 2 - 1 . 4 5 ) 2 1 4  ( 3 8 .4 ) 2 7 0  ( 3 3 .9 ) 0 .1 2 0 .2 1 0 .S 2  ( 0 . 6 5 - 1 . 0 5 )
r s 2 2 S 0 2 7 5 T /T 2 5 8  ( 7 1 .1 ) 3 4 6  ( 7 0 .9 ) 0 .6 6 O .SS 1 .0 0 2 1 4  ( 7 7 .3 ) 2 8 6  ( 6 7 .5 ) 0.01 0.04 1 .0 0
T /C 1 0 1  ( 2 7 .8 ) 1 3 3  ( 2 7 .3 ) 0 .9 6  ( 0 . 7 0 - 1 . 3 5 ) 5 7  ( 2 0 .6 ) 1 2 5  ( 2 9 .5 ) 1 .5 9  ( 1 . 1 0 - 2 . 3 7 )
C /C 4 ( 1 . 1 ) 9 ( 1 . 8 ) 1 .5 9  ( 0 . 5 8 - 5 . 1 4 ) 6  ( 2 .2 ) 1 3  ( 3 .1 ) 1 .3 5  ( 0 . 5 1 - 3 . 6 4 )
C 1 0 9  ( 1 5 .0 ) 1 5 1  ( 1 5 .5 ) 0 .8 4 0 .9 9 1 .0 4  ( 0 . 8 1 - 1 . 3 7 ) 6 9  ( 1 2 .5 ) 1 5 1  ( 1 7 .8 ) 0.01 0.03 1 .5 0  ( 1 . 1 1 - 2 . 0 5 )
r s 7 5 1 5 2 S 9 A / A 1 9 5  ( 5 3 .4 ) 2 6 2  ( 5 3 .7 ) 0 .2 7 0 .8 3 1 .0 0 1 5 4  ( 5 5 .0 ) 2 2 0  ( 5 1 .9 ) 0 .4 7 0 .5 9 1 .0 0
A /C 1 5 3  ( 4 1 .9 ) 1 9 1  ( 3 9 .1 ) O .SS  ( 0 . 6 6 - 1 . 2 2 ) 1 0 0  ( 3 5 .7 ) 1 7 0  ( 4 0 .1 ) 1 .2 1  ( 0 . S 9 - 1 . 6 3 )
C /C 1 7  ( 4 .7 ) 3 5  ( 7 .2 ) 1 .5 4  ( 0 . 8 9 - 2 . 9 4 ) 2 6  ( 9 .3 ) 3 4  ( 8 .0 ) 0 .8 3  ( 0 . 4 9 - 1 . 4 6 )
C 1 8 7  ( 2 5 .6 ) 2 6 1  ( 2 6 .7 ) 0 .6 5 0 .9 9 1 .0 5  ( 0 . 8 7 - 1 . 3 9 ) 1 5 2  ( 2 7 .1 ) 2 3 8  ( 2 8 .1 ) 0 .7 3 0 .7 9 1 .0 3  ( 0 . 8 5 - 1 . 4 1 )
r s l 1 5 7 2 3 2 5 A / A 2 9 6  ( 8 1 .1 ) 3 9 8  ( 8 2 .2 ) 0 .6 1 O .SS 1 .0 0 2 4 2  ( 8 6 .4 ) 3 2 6  ( 7 6 .9 ) 0.02 0.05 1 .0 0
A /T 6 7  ( 1 8 .4 ) 8 1  ( 1 6 .7 ) O .SS  ( 0 . 6 1 - 1 . 2 9 ) 3 5  ( 1 2 .5 ) 9 2  ( 2 1 .7 ) 1 .8 9  ( 1 . 2 2 - 2 . 9 5 )
T /T 2  ( 0 .5 ) 5  ( 1 .0 ) 1 .6 5  ( 0 . 4 2 - 7 . 7 8 ) 3  ( 1 .1 ) 6  ( 1 .4 ) 1 .2 2  ( 0 .3 4 —4 .5 9 )
T 7 1  ( 9 .7 ) 9 1  ( 9 .4 ) 0 .8 8 0 .9 4  ( 0 . 6 6 - 1 . 4 4 ) 4 1  ( 7 .3 ) 1 0 4  ( 1 2 .3 ) 0.006 0.02 1 .7 4  ( 1 . 1 9 - 2 . 5 8 )
r s lO S S 9 1 6 2 G / G 3 0 8  ( 8 5 .6 ) 4 0 3  ( 8 5 .9 ) 0 .3 1 0 .8 3 1 .0 0 2 4 4  ( 8 7 .8 ) 3 4 7  ( 8 2 .4 ) 0 .1 2 0 .2 4 1 .0 0
G / A 5 2  ( 1 4 .4 ) 6 3  ( 1 3 .4 ) 0 .9 3  ( 0 .6 1 - 1 .3 S ) 3 1  ( 1 1 .2 ) 7 1  ( 1 6 .9 ) 1 .6 1  ( 1 . 0 0 - 2 . 5 6 )
A / A 0  ( 0 .0 ) 3  ( 0 .6 ) - 3  ( 1 .1 ) 3  ( 0 .7 ) 0 .6 5  ( 0 . 1 3 - 3 . 2 4 )
A 5 2  ( 7 .2 ) 6 9  ( 7 .4 ) 0 .9 9 0 .9 9 1 .0 1  ( 0 . 6 9 - 1 . 5 3 ) 3 7  ( 6 .7 ) 7 7  ( 9 .1 ) 0 .1 3 0 .2 1 1 .4 1  ( 0 . 9 5 - 2 . 1 7 )
Statistically significant P-values and <2-values are bolded
“Absolute number and percentage of individuals/chromosomes with particular genotype/allele 
bOdds ratio with 95% confidence intervals adjusted for age and BMI
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population were postmenopausal). The results are shown in 
Supplementary Table 2. Although the group of pre­
menopause women was too small (85 EH patients and 56 
controls), all three polymorphisms tended to be associated 
with the risk of EH in both the pre- and post-menopausal 
women, which suggests that sex hormones do not explain 
the relationship between the SNPs and disease risk in 
women.
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Interactions between SNPs of CYP2J2 and risk of EH
To investigate whether interactions between SNPs of 
CYP2J2 contribute to the disease risk, we performed an 
association analysis of genotype combinations with EH risk 
in gender-stratified groups. Table 4 summarizes the sig­
nificant associations identified between CYP2J2 genotype 
combinations and the risk of EH. Twenty-seven genotype 
combinations showed significant associations with the risk 
of EH in females. Notably, eight of these associations were 
due to SNP-SNP interactions that involved polymorphism 
rs890293, whereas the SNP rs2280275 was identified in 
eight genotype combinations associated with hypertension 
risk in females. Moreover, six disease-associated genotype 
combinations in females included the rs11572325 geno­
types. As shown in Table 4, only four CYP2J2 genotype 
combinations were associated with the risk of EH in males.
Table 5 shows the estimated CYP2J2 haplotypes and 
their associations with hypertension risk in females and 
males. Eight common CYP2J2 haplotypes (frequency > 1%) 
were identified in both males and females. Haplotypes H1 
(G-T-G-C-T-A-A-G) and H2 (G-T-G-T-T-A-A-G) were 
found in approximately 60% of the studied individuals. A 
significant difference in the distribution of haplotypes was 
observed between the hypertensive and normotensive 
females (P =  0.0052), whereas no significant difference in 
the haplotype distribution was identified between the 
hypertensive and normotensive males (P =  0.22). Haplo- 
type H5 (T-T-G-C-C-C-T-A) was found to be associated 
with an increased risk of EH in females (OR =  1.70, 95%CI 
1.02-2.84, P = 0.041). It is important to note that the rare 
haplotypes (frequency<1%, Supplementary Table 3) 
showed a significant association with hypertension sus­
ceptibility in both females (adjOR =  4.17, 95%CI
1.21-14.23, P = 0.024) and males (adjOR =  2.81, 95%CI 
1.16-6.94, P = 0.027).
Figure 1 shows the pairwise linkage disequilibrium 
coefficients (D' and r) between the SNPs of the CYP2J2 
gene in females and males. All investigated SNPs were in 
linkage disequilibrium to each other with various degrees. 
In particular, the D '-values between SNPs rs890293 and 
rs1155002, rs890293 and rs11572325, and rs1155002 and 
rs10889162 were stronger in the males than in the females, 
whereas the D '-values between the polymorphisms
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Table 4 Associations between CYP2J2 genotype combinations and with the risk of essential hypertension
№ Genotype combinations Healthy controls, N  (%)a EH patients, N  (%)a P-value Q-value adjOR (95% CI)b
Females (425 cases, 280 controls)
1 rs11572182TT/rs890293GT 16 (6.5) 51 (14.2) 0.006 0.018 2.31 (1.30-4.19)
2 rs10493270GG/rs890293GT 19 (7.7) 57 (15.9) 0.005 0.016 2.20 (1.25-3.94)
3 rs2280275AA/rs890293GG 184 (75.7) 233 (65.1) 0.008 0.018 0.62(0.44-0.89)
4 rs2280275AG/rs890293GT 16 (6.6) 54 (15.1) 0.004 0.016 2.44 (1.32-4.65)
5 rs2280275AG / rs11572182TT 31 (11.2) 82 (19.3) 0.008 0.018 1.87 (1.20-2.92)
6 rs2280275AA/rs10493270GG 163 (58.8) 213 (50.2) 0.042 0.045 0.70 (0.54-0.97)
7 rs2280275AG/rs10493270GG 47 (17.0) 110 (25.9) 0.008 0.018 1.68(1.14-2.78)
8 rs2280275AG/rs1155002CC 31 (11.2) 69 (17.4) 0.047 0.047 1.64 (1.03-2.60)
9 rs7515289AC/rs890293GT 16 (6.5) 48 (13.4) 0.019 0.027 2.14 (1.17-3.97)
10 rs7515289AC/rs11572182TT 33 (11.8) 81 (19.1) 0.025 0.032 1.74 (1.12-2.72)
11 rs7515289AC/rs2280275AG 43 (15.5) 108 (25.5) 0.003 0.016 1.83 (1.23-2.76)
12 rs11572325AA/rs890293GG 209 (85) 258 (72.1) 0.0004 0.011 0.47 (0.31-0.71)
13 rs11572325AT/rs890293GT 19 (7.7) 52 (14.5) 0.019 0.027 1.98 (1.14-3.58)
14 rs11572325AT/rs11572182TT 17 (6.1) 51 (12.0) 0.021 0.028 2.03 (1.16-3.67)
15 rs11572325AA/rs11572182GT 61 (21.8) 65 (15.3) 0.042 0.045 0.66 (0.45-0.97)
16 rs11572325AA/rs10493270GG 189 (67.5) 247 (58.3) 0.019 0.027 0.69 (0.51-0.94)
17 rs11572325AT /rs10493270GG 27 (9.6) 83 (19.6) 0.0009 0.012 2.24 (1.40-3.59)
18 rs11572325AT/rs1155002CT 13 (4.7) 39 (9.8) 0.026 0.032 2.17 (1.14-4.14)
19 rs11572325AA / rs2280275AA 214 (77.3) 281 (66.4) 0.005 0.016 0.59 (0.43-0.86)
20 rs11572325AT/rs2280275AG 31 (11.2) 83 (19.6) 0.005 0.016 1.90 (1.20-3.02)
21 rs11572325AT/rs7515289AC 27 (9.6) 71 (16.8) 0.013 0.023 1.86 (1.15-2.97)
22 rs10889162GG//rs890293GG 213 (87.3) 280 (78.7) 0.012 0.023 0.55 (0.35-0.86)
23 rs10889162GA/rs890293GT 22 (9.0) 56 (15.7) 0.028 0.032 1.84 (1.09-3.04)
24 rs10889162GG/rs2280275AA 211 (76.7) 278 (66.2) 0.005 0.016 0.62 (0.44-0.85)
25 rs10889162GA/rs2280275AG 24 (8.7) 60 (14.3) 0.044 0.045 1.70 (1.03-2.80)
26 rs10889162GG/rs11572325AA 229 (82.4) 312 (74.1) 0.017 0.027 0.63 (0.43-0.95)
27 rs10889162GA/rs11572325AT 19 (6.8) 57 (13.5) 0.009 0.018 2.02 (1.20-3.62)
Males (488 cases, 365 controls)
1 rs1155002TT/rs10493270GG 33 (9.1) 60 (14.3) 0.040 0.045 1.64 (1.04-2.56)
2 rs2280275AA/rs1155002TT 33 (9.1) 60 (14.3) 0.042 0.045 1.64 (1.04-2.56)
3 rs11572325AA/rs1155002TT 33 (9.1) 59 (14.1) 0.045 0.045 1.63 (1.03-2.55)
4 rs10889162GG/rs1155002TT 33 (9.2) 59 (14.7) 0.038 0.045 1.66 (1.05-2.62)
Q-values at < 0.05 mean statistically significant associations after adjustment for multiple tests by the FDR method 
“Absolute number and percentage of individuals with particular genotype combination 
bOdds ratio with 95% confidence intervals adjusted for age and BMI
rs11572325 and rs10493270 were stronger in the females 
than in the males (D'-values that differed between males and 
females are indicated in bolded cells in Fig. 1).
A comprehensive functional analysis of CYP2J2 
polymorphisms
To evaluate genotype-phenotype correlations, we used the 
genotype and mRNA expression data for the CYP2J2 gene, 
which were obtained from the GTEx project. The relative 
expression levels of CYP2J2 mRNA by different genotypes
are shown in Fig. 2. The levels of CYP2J2 mRNA were 
significantly correlated with SNPs rs1155002 (P =  0.0002) 
and rs10493270 (P =  0.015), as evaluated by T-statistics. 
No significant genotype-phenotype correlations were iden­
tified for the other investigated SNPs.
Functional prediction analysis performed in silico by the 
SNP Function Prediction tool revealed indicated the func­
tionality of several polymorphisms (Table 5, Supplementary 
Tables 4-6). In particular, a regulatory potential was iden­
tified for SNPs rs890293, rs10493270, rs1155002, 
rs2280275 and rs7515289. The polymorphisms rs890293,
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Table 5 Associations between haplotypes of CYP2J2 and the risk of essential hypertension
Haplotypes SNPs Frequency P-value adjOR (95%CI)b
rs890293 rsll572182 rs 10493270 rsl 155002 rs2280275 rs7515289 rsl 1572325 rsl0889162 Healthy controls EH patients
Females (705 
HI
subjects) 
G T G C T A A G 0.3761 0.3704 1.00
H2 G T G T T A A G 0.2400 0.2333 0.971 1.01 (0.76-1.32)
H3 G G G T T C A G 0.1373 0.0965 0.072 0.74 (0.52-1.08)
H4 G T A c T A A G 0.1125 0.1059 0.812 0.94 (0.66-1.41)
H5 T T G c c C T A 0.0427 0.0712 0.041 1.70 (1.02 - 2.84)
H6 G G G c c C T G 0.0375 0.0368 0.341 1.35 (0.77-2.49)
H7 G T G c c c A G 0.0305 0.0415 0.970 0.99 (0.58-1.75)
H8 G T G c c c A A 0.0161 0.0106 0.491 0.71 (0.28-1.83)
Rare3 * * * * * * * * 0.0073 0.0338 0.023 4.13 (1.21-14.26)
Global haplotype association P-value: 0.0052 
Males (853 subjects)
HI G T G c T A A G 0.4064 0.3755 1.00
H2 G T G T T A A G 0.2358 0.2482 0.331 1.15 (0.89-1.45)
H3 G G G T T C A G 0.1027 0.1077 0.457 1.12 (0.80 - 1.78)
H4 G T A c T A A G 0.1003 0.0935 0.914 1.04 (0.76-1.82)
H5 T T G c c C T A 0.0533 0.0488 0.972 1.02 (0.61-1.66)
H6 G G G c c C T G 0.0398 0.0316 0.673 0.91 (0.54-1.72)
H7 G T G c c c A G 0.0355 0.0468 0.248 1.38 (0.81-2.73)
H8 G T G c c c A A 0.0150 0.0149 0.774 1.12 (0.50 - 2.81)
Rare3 * * * * * * * * 0.0112 0.0330 0.027 2.82 (1.14-6.65)
Global haplotype association P-value: 0.234 
Statistically significant associations are bolded
“Rare haplotypes with frequency <0.01 are shown in Supplementary Table 2 
bOdds ratio with 95% confidence intervals adjusted for age and BMI.
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Fig. 1 Linkage disequilibrium 
between SNPs of CYP2J2 in 
females and males. The upper 
part of the matrix contains 
(above the diagonal) the LD- 
values between SNPs in 
females. The lower triangle 
(below the diagonal) contains 
the LD-values between SNPs in 
males. Gray cells represent D - 
values, whereas white cells 
represent r-values of LD.
Bolded cells show D'-values 
that differ between males and 
females. All LD-values in the 
matrix are statistically 
significant
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rs11572182, and rs10889162 of CYP2J2 were found to be 
located within the binding sites for multiple transcription 
factors, as evaluated by the TRANSFAC and/or rSNPBase 
databases. SNPs rs10493270, rs1155002, rs2280275, 
rs7515289 and rs11572325 were identified to have the 
potential for the regulation of CYP2J2 gene expression at 
the post-transcriptional level through an RNA-binding 
protein-mediated mechanism. Expression quantitative trait 
loci, or eQTLs, were found for polymorphisms rs10493270, 
rs1155002 and rs2280275. These data demonstrate the 
functionality for a majority of the investigated polymorph­
isms, including those associated with hypertension risk in 
our study.
Discussion
Polymorphisms of CYP2J2 and their relationship 
with hypertension pathogenesis
To date, only seven studies have been conducted to assess 
associations between polymorphisms of the CYP2J2 gene 
and hypertension susceptibility: four studies in Caucasians 
[20, 28, 31, 33], two studies in Asians [30, 32] and one 
study in blacks [29]. Five of these studies investigated the 
association of hypertension with the only one SNP 
rs890293 (-5 0  or —76G>T) located at the promoter of 
CYP2J2 in small population samples (<200 EH patients). 
Only one study performed by Fava and colleagues [20] 
investigated the relationship among the rs890293 poly­
morphism, blood pressure and hypertension risk in a large 
urban-based sample of Swedes with hypertension (N = 
1858). The results from these studies have been conflicting: 
two studies performed in Russian [31] and Saudi Arabian 
[32] populations indicated a strong positive association
between SNP rs890293 and hypertension risk; in contrast, 
one study in white Americans showed a negative associa­
tion of this polymorphism and disease risk [28], whereas 
studies conducted in Swedish [20], Bulgarian [33] and 
African American [29] populations did not identify a rela­
tionship between the SNP and hypertension susceptibility. 
Another study performed on a sufficient number of cases 
and controls (415 hypertensives and 426 normotensive 
individuals) from the Chinese Han population investigated 
eight SNPs of CYP2J2; however, one half of them 
(including SNP rs890293) exhibited an MAF <3% [30]. 
This study indicated a relationship between SNP rs1155002 
and systolic blood pressure and hypertension risk in 
females, a finding that was not supported by the results of 
our study. The present study confirmed the results of our 
previous study performed on an independent sample of 295 
cases and 281 controls of Russian origin from the Kursk 
region [31]. This study reported a positive association of 
SNP rs890293 with hypertension risk.
The present study investigated eight common SNPs 
(minor allele frequency >5%) of CYP2J2 and identified 
significant associations of three SNPs, including rs890293, 
rs2280275, and rs11572325, with the risk of EH exclusively 
in females. We found that the haplotype T-T-G-C-C-C-T-A 
is associated with an increased risk of EH in females. In 
addition, the rare CYP2J2 haplotypes that contain the var­
iant alleles at the three SNPs rs890293 (T), rs2280275 (C) 
and rs11572325 (T) prevailed in hypertensives compared 
with healthy individuals non-depending on their sex (Sup­
plementary Table 3). Furthermore, we identified sixteen 
CYP2J2 genotype combinations associated with EH risk in 
females, and the strengths of the associations were greater 
for genotype combinations than for the genotypes alone. 
Interestingly, these genotype combinations comprise the 
rs890293, rs2280275 and rs11572325 polymorphisms, each
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Fig. 2 Impact of polymorphisms on CYP2J2 gene expression. The 
charts show the relative expression levels of the CYP2J2 gene mRNA 
(rank normalized gene expression) by different genotypes in the 
samples of tibial arteries obtained from 285 postmortem individuals as 
a part of the GTEx project. GTEx (Genotype-Tissue Expression) is a 
project created to establish a sample and data resource for studies on
the relationship between genetic variation and gene expression in 
multiple human tissues to identify expression quantitative trait loci, or 
eQTLs. The data used for the analyses described in the manuscript 
were obtained from the GTEx Portal (https://www.gtexportal.org), 
dbGaP accession number phs000424.v6.p1 on 07/14/2017
of which showed an association with disease risk. This 
finding suggests that these SNPs represent trans-acting 
modifiers that have the potential to modulate the expression 
and/or activity of the CYP2J2 gene. To our knowledge, this 
investigation is the first study to identify associations 
between polymorphisms rs2280275 and rs11572325 of the 
CYP2J2 gene and the risk of EH. Interestingly, SNPs
rs2280275 and rs11572325 have been found to be related to 
the risk of coronary artery disease [23] and myocardial 
infarction [19], respectively. In particular, Zhu and co­
workers reported that a carriage of allele T of rs2280275 is 
associated with an increased risk of coronary artery disease 
in men of the Uygur population from China, whereas no 
statistically significant association of this SNP was
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identified in women [23]. Thus, this SNP showed the same 
trend in association with an increased risk of EH in our 
population but, in contrast, only in women. Zhu with co­
workers suggested that the sex-specific association identi­
fied may be modified by estrogens, which are known to 
protect vascular cells against oxidative stress and may also 
protect the EETs against being hydrolyzed by soluble 
epoxide hydrolase [23]. We suppose that a sex-specific 
association between SNP rs2280275 and hypertension risk 
in our population could be modified by not established risk 
factors that influence the disease risk. The study of Mar- 
ciante and co-workers [19] indicated that the polymorphism 
rs11572325 of CYP2J2 is associated with an increased risk 
of myocardial infarction that does not depend on sex, age, 
hypertension and other confounding factors. SNPs 
rs2280275 and rs11572325 are located in intronic sequen­
ces of the gene, and they cannot directly influence the 
expression or activity of CYP2J2. However, the poly­
morphisms are in a positive linkage disequilibrium with the 
regulatory SNP rs890293 (Fig. 1) located in the promoter of 
the CYP2J2 gene and interrupting a critical binding site for 
the transcription factor Sp1, thus resulting in decreased 
promoter activity in vitro and reduced levels of CYP2J2 
epoxygenase metabolites in vivo [45, 46]. Moreover, the 
polymorphisms rs890293, rs2280275 and rs11572325 col­
lectively contribute to the activity and/or expression of 
CYP2J2 and thus influence the biosynthesis of vasoactive 
EETs. The bioinformatic analysis (Table 6) enabled the 
identification of the RNA-binding protein ELAVL1, which 
has the potential to influence the stability of mRNA and 
potentially the expression of CYP2J2 at the posttranscrip­
tional level via interaction with the polymorphisms 
rs2280275 and rs11572325; moreover, the biological effects 
of the ELAVL1 protein have been demonstrated for some 
genes [47, 48]. It is plausible to assume that posttransla­
tional modification of the CYP2J2 transcript by ELAVL1 
may represent an important mechanism implied in the 
vascular regulation of epoxygenase activity. However, 
before definitive conclusions may be made, experimental 
studies that investigate the effects of ELAVL1 on the 
activity or expression of CYP2J2 are required. Finally, the 
mechanisms by which individuals with this genetic variant 
might be more susceptible to hypertension include: a) 
endothelial dysfunction; b) decreased ion channel- 
dependent vasodilatation; c) enhanced epithelial sodium 
channel activity; d) increased cortical renin release; e) 
decreased renal blood flow; and f) increased cardiac con­
tractility and heart rate [10, 49].
Functionality of SNPs and expression of CYP2J2
Functional studies of the common polymorphisms of the 
CYP2J2 gene in the literature are limited to only SNP
rs890293. To evaluate the phenotypic effects of the studied 
SNPs, we used the CYP2J2 genotype and mRNA expres­
sion data in peripheral (tibial) arteries obtained from the 
GTEx project. The levels of CYP2J2 mRNA were corre­
lated with the polymorphisms rs1155002 and rs10493270, 
whereas the SNPs associated with hypertension risk showed 
no relationship with the CYP2J2 expression. The incon­
sistency of these data may be explained by differences in 
the samples and analytical methods used, as well as a var­
iation in the CYP2J2 transcript levels across tissues as 
analyzed by the GTEx project (these data are available at 
www .gtexportal.org).
Because of the limited data on the functional significance 
of the investigated SNPs, we performed an in silico analysis 
of the regulatory potential for all polymorphisms using 
various bioinformatic tools. The bioinformatic analysis 
indicated the functionality of three SNPs (rs890293, 
rs2280275, and rs11572325) associated with EH. In parti­
cular, the SNPs possess a regulatory potential (excluding 
rs11572325) as identified by the SNP Function Prediction 
tool. All three SNPs are identified as rSNP (regulatory 
polymorphisms) and are in LD with other rSNPs according 
to the rSNPbase data. In addition, the intronic polymorph­
isms rs2280275 and rs11572325 have the potential to be 
regulated at the posttranslational level through an RNA 
binding protein-mediated mechanism. We identified 
numerous transcription factors related to the polymorphism 
rs890293 of CYP2J2, which are worthwhile to note because 
they are involved in various biological processes in the 
cardiovascular system, may regulate blood pressure and 
may be related to hypertension pathogenesis (data obtained 
from the Gene Ontology database, www.geneontology.org). 
For example, the CYP2J2 gene expression may be directly 
regulated by the PPARA (Peroxisome Proliferator Acti­
vated Receptor Alpha) signaling pathway (GO:0035357) 
through an interaction of the transcription factor TEAD2 
(TEA domain transcription factor 2) with the promoter SNP 
rs890293. TEAD2 is known to be involved in the pathways 
that regulate vasculogenesis (GO:0001570) and embryonic 
heart tube morphogenesis (GO:0003143). Transcription 
factor NF1 (neurofibromin 1) is involved in many biological 
processes in the heart and vessels, such as the negative 
regulation of endothelial cell proliferation (GO:0001937), 
positive regulation of endothelial cell proliferation 
(GO:0001938), heart development (GO:0007507), regula­
tion of angiogenesis (GO:0045765), negative regulation of 
angiogenesis (GO:0016525) and regulation of blood vessel 
endothelial cell migration (GO:0043535). Transcription 
factors, such as PAX6 (paired box 6) and E2F4 (E2F 
transcription factor 4), are important components of the 
pathways involved in the regulation of blood vessel 
development (GO:0001568) and blood circulation 
(GO:0008015), respectively. Two intronic polymorphisms
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Tab le  6 Bioinformatic analysis for the regulatory potential of the studied single nucleotide polymorphisms of the CYP2J2 gene
SNP ID Allele Location SNP Function Prediction Regulatory annotations on SNPs (rSNPBase)b TFBS and Gene Sets associated with SNP
withi gene (FuncPred)3
TFBS miRNA Regulatory rSNP LD- Proximal Distal miRNA RNA binding eQTL TRANSFAC Database rSNPBase
potential proxy 
of rSNP 
(r2 >0.8)
regulation regulation regulation protein medi­
ated regulation
rs890293 G/T 5'UTR Yes No 0.1494 Yes Yes Yes No No No No CACD, ETF (TEAD2), IK, 
MYOG/NF1, PAX6, SP1, 
VDR
Max, E2F6, Pol2, 
c-Myc, CHD2, 
TBP, MAZ, 
MXI1, UBTF, 
E2F4
rsl 1572182 T/G 5'UTR Yes No No Yes Yes Yes No No No No I.FF1, TCF1, PEZF 
(ZBTB16), PPARA, 
PPARG, SPZ1, TBP
rsl0493270 G/A intron No No 0.0674 Yes No No No No Yes Yes - ELAVLl3
rsl 155002 C/T intron No No 0.1567 Yes Yes No No No Yes Yes - ELAVLl3
rs2280275 T/C intron No No 0.1126 Yes Yes No No No Yes Yes - ELAVLl3
rs7515289 A/C intron No No 0.1456 Yes Yes Yes No No Yes No - ELAVLl3
rsl 1572325 ATT intron No No No Yes Yes No No No Yes No - ELAVLl3
rsl0889162 G/A 5'UTR Yes No No Yes Yes Yes No No No No AIRE, CDPCR3_01, 
GRE_C, HAND 1E47_01, 
MYOGNF1_01, RAX5, 
PAX6, PAX8
TFBS, transcription factor binding sites predicted by the TRANSFAC database on potential transcription factors, their genomic binding sites and DNA binding profiles (BIOBASE Corporation, 
Wolfenbuettel, Germany, http://gene-regulation.com) and available via the SNP Function Prediction tool (National Institute of Environmental Health Sciences (https://snpinfo.niehs.nih.gov/ 
snpinfo/snpfunc.php)
The only TFBS whose core or matrix match score was impacted, or which were eliminated or created by variant sequences were included in this table to be regulatory within a particular SNP (all 
TFBS identified by TRANSFAC are listed in Supplementary Tables 3-5) 
rSNPBase is a database of curated regulatory SNPs (http://rsnp.psych.ac.cn).
aPost-transcriptional regulation: associated with RNA binding protein. Gray cells indicate SNPs associated with hypertension susceptibility in the present study
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rs2280275 and rs11572325 associated with hypertension 
risk are located within specific sites for ELAVL1, a mRNA- 
binding protein that binds to the 3'-UTR region of mRNAs 
and increases their stability [47]. Interestingly, this mRNA- 
stabilizing protein participates in biological processes, such 
as the regulation of blood vessel endothelial cell migration 
(GO:0043535) and the positive regulation of blood vessel 
endothelial cell migration (GO:0043536).
Nevertheless, it is unclear which of the three disease- 
associated SNPs possesses a phenotypic effect on the dis­
ease development because the promoter (rs890293) and 
intronic (rs2280275 and rs11572325) polymorphisms are in 
strong positive linkage disequilibrium to each other (Fig. 1). 
We suggest that the non-coding rs2280275 and rs11572325 
variants, which are in close proximity to the rs890293 
polymorphism, may act as cis-acting modifiers that influ­
ence the transcriptional activity of the CYP2J2 gene, a well- 
known mechanism for the regulation of gene expression 
[50]. At the very least, this suggestion can be supported by 
our finding that the frequency of the haplotype T-T-G-C-C- 
C-T-A (the variant alleles for each SNP are underlined) was 
higher in hypertensive than normotensive females. How­
ever, it remains unclear whether the effects of these SNPs 
on disease risk are attributed to their synergism or the 
linkage disequilibrium between them.
Sex dimorphism and hypertension susceptibility
The main finding of our study is a sex-specific association 
between single nucleotide polymorphisms of the CYP2J2 
gene and the risk of EH. The SNPs rs890293, rs2280275 
and rs11572325 alone and in combinations with each other 
and other CYP2J2 SNPs were associated with an increased 
risk of EH exclusively in females, even when the associa­
tions were assessed separately in pre- and post-menopausal 
women. Rare haplotypes have been associated with hyper­
tension susceptibility in both sexes; however, the strength of 
this association was stronger in females than in males. As 
indicated in the literature [30, 51], only one study per­
formed in a Chinese population has identified a female- 
specific effect of the CYP2J2 gene polymorphism 
(rs1155002) on hypertension susceptibility.
The observed intergroup difference in the frequency 
of rare haplotypes may be related to the sex-specific dif­
ference in the recombination rates between sexes. It is 
well recognized that the number of recombination rates 
per meiosis differs between females and males and seems 
to be tightly regulated [52]. Moreover, recombination 
events occur nearly 2-fold higher in female meiotic divi­
sions than in male meiosis, whereas the crossover recom­
bination rates in males are 5-fold lower near the centromere 
regions of chromosomes and 10-fold higher near telomeres 
than those in females [53]. As indicated in Fig. 2, the
LD coefficients between the SNP rs890293 and rs2280275 
or rs11572325 (polymorphisms associated with EH risk 
in our study) were weaker in females than in males. 
This finding suggests that the phenotypic effects of 
these SNPs on the disease risk may differ in females and 
males. Moreover, it may particularly explain why the 
SNPs were associated with EH risk only in females. Sex- 
specific differences in recombination events are thought 
to be related to the effect of sex [54] or may result from 
differences in the genetic regulation of female and male 
meiosis [55].
The observed sex-specific difference in the contribution 
of the CYP2J2 polymorphisms to hypertension suscept­
ibility may be attributed to the regulatory effects of sex 
hormones on gene expression or activity. Estrogens are 
well known to be protective against hypertension and 
cardiovascular disease [56, 57] and may protect the EETs 
against being hydrolyzed by soluble epoxide hydrolase 
[58, 59]. Nevertheless, estrogen was found to be responsible 
for significant sex-specific differences in autonomic func­
tion in patients with hypertension: the baroreceptor 
reflex sensitivity and heart rate variability are more impaired 
in hypertensive women than in men [60, 61]. Undoubtedly, 
we cannot exclude that the female-specific association 
between the polymorphisms of the CYP2J2 gene and 
the hypertension risk may be explained by sex differences 
in the major hemodynamic parameters determined by 
well documented anatomical and physiological features 
of the cardiovascular system in women [62- 65]. As the 
hemodynamic parameters were not measured in our 
hypertensive patients, we could not evaluate whether 
these parameters explain the sex difference in hypertension 
susceptibility.
It is established that sex hormones possess regulatory 
effects on gene expression. It has been reported that the 
hormone в -estradiol has the potential to increase the levels 
of CYP2J2 mRNA in a concentration-dependent manner, 
while testosterone has been shown to decrease transcript 
levels of the gene in human cardiomyocytes [66], a finding 
that may explain the sex-specific association between 
CYP2J2 SNPs and hypertension identified in our study. In 
contrast, an experimental study of Ma and co-workers [67] 
showed that the renal expression of the mouse ortholog 
CYP2J5 (analogue of CYP2J2 in humans) is down- 
regulated by estrogen and upregulated by androgen. How­
ever, Athirakul and colleagues [68] indicated that deficiency 
of CYP2J5 in female mice was associated with increased 
blood pressure, enhanced proximal tubular transport rates, 
and exaggerated afferent arteriolar responses to angiotensin 
II and endothelin I, thus illustrating a sex-specific role for 
CYP2J5 in the regulation of blood pressure, proximal tub­
ular transport, and afferent arteriolar responsiveness via an 
estrogen-dependent mechanism. Thus, it is reasonable to
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speculate that the expression of CYP2J2 and the associated 
biosynthesis of EETs may influence blood pressure through 
interaction with estrogen.
Furthermore, the bioinformatic analysis enabled the 
identification of the transcription factor MYOG (myogenin) 
capable of affecting the expression of CYP2J2 via interac­
tion with the SNP rs890293 at the gene promoter. Inter­
estingly, this transcription factor is related to a pathway 
that regulates the cellular response to estradiol stimuli 
(GO:0071392), thereby indicating that the association of the 
polymorphism rs890293 with hypertension risk in females 
is somehow connected to the actions of estrogen and its 
effects may down-regulate the expression of CYP2J2 in the 
carriers of allele —50T, resulting in a decreased biosynthesis 
of EETs. In addition, the transcription factor binding site for 
TEAD2 located at the SNP rs890293 (Table 3) is related to 
the pathways that regulate many biological processes in 
females. In particular, we identified the following enriched 
GO terms of partners interacting with the transcription 
factor TEAD2: the positive regulation of female receptivity 
(GO:0045925), hormone-mediated signaling pathway 
(GO:0009755), intracellular steroid hormone receptor sig­
naling pathway (GO:0030518) and progesterone receptor 
signaling pathway (GO:0050847). Undoubtedly, further 
systems biology studies are required to obtain a better 
understanding of the complexity of the interrelationship 
among CYP2J2, sex hormones, EETs and blood pressure 
regulation.
Study limitations
The results of our study should be interpreted in the 
context of several limitations. The low genotype call rate 
for several SNPs of CYP2J2 did not allow their inclusion 
in the study or a more comprehensive analysis of the 
contribution of the selected SNPs to the risk of EH. The 
case/control ratio in our study samples was 1.4, which 
indicates that the matching of hypertensive patients and 
healthy controls was suboptimal. A gender-specific asso­
ciation analysis was performed in a post-hoc manner on 
a sample of relatively low size; thus, the findings on the 
relationship between SNPs and hypertension risk in 
females must be carefully interpreted. Moreover, the inter­
actions of the studied SNPs of the CYP2J2 gene with 
other potential confounding factors, such as sex hormones 
and/or disease-related environmental risk factors in hyper­
tensive females, were unexplored in the present study, 
which does not enable conclusions to be drawn with 
respect to the sex-specific relationship between the poly­
morphisms and disease risk. The mechanisms by which 
estrogens exert their regulatory effects on hypertension 
susceptibility through the modulation of CYP2J2 gene 
expression remained to be elucidated in further studies.
Thus, the study results should be considered preliminary, 
and further investigation in independent cohorts of hyper­
tensive patients and controls is required to replicate the sex- 
specific associations of the studied SNPs of the CYP2J2 
gene and hypertension susceptibility.
Conclusions
The current findings show that polymorphisms of the 
CYP2J2 gene may represent important determinants of 
susceptibility to EH and that their effects on disease risk are 
joint and sex-specific. We found for the first time that the 
rs2280275 and rs11572325 SNPs of CYP2J2 could be 
novel genetic markers of susceptibility to EH, at least in 
Russian females. As this study reports a preliminary asso­
ciation between new SNPs of the CYP2J2 gene and 
hypertension risk in females, a replication study in an 
independent population is warranted. Further studies will 
provide insights into the mechanisms that underlie the 
sexual dimorphism in the relationship among CYP2J2 
polymorphisms, gene expression and hypertension patho­
physiology with the purpose of determining the most ben­
eficial therapeutic options for the management of EH in 
women and men, expanding opportunities for the clinical 
application of pharmacogenetics and personalized medicine 
[69, 70].
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